5 / 16
Page 35
Notes:
allied
academies
Biol Med Case Rep 2017 | Volume 1 Issue 2
November 06-07, 2017 | New Orleans, USA
Nanomedicine & Healthcare
Global Meet on
N
anosciences covers a clear majority of devices derived
from biology, engineering and basic sciences which
contain nanovectors for the drug delivery system in
anticancer drugs. There have been available nanoparticles
with various characteristics for optimal drug delivery e.g.
for increasing their stability in the circulation system and
targeted delivery to the tumors by taking the advantage of
enhanced permeability and retention effect near the tumor
tissue. Evaluation of the mechanisms and therapeutic effects
of nanoparticle-based mammalian mechanistic target of
rapamycine (mTOR) modulation can be useful in developing
safe in treatment of cancer. mTOR is a conserved serine/
threonine kinase in the cellular PI3K/Akt/mTOR signaling
pathway. This pathway is modified by cellular alterations
such as level of energy, growth factors, stresses, as well as
the increased environmental level of cancerous cytokines.
In general, increase of this kinase protein function is seen
in various types of cancers, especially in cancer stem-like
cell. Additionally, activation of this pathway in the most
common cancers like nervous system is in consideration.
Recent studies have shown the relationship between
different cellular signaling pathways and genetic mutations,
that involved in the cancers, with mTOR pathway. Based
on previous studies, different treatments like surgery,
chemotherapy, radiotherapy, aren’t more effective and have
some side-effects. Therefore, the researchers are trying to
find better ways to treat cancer. One approach to this aim is
about the essence of understanding all molecular pathways,
proteins and mutations.
Speaker Biography
Abbas Ebrahimi-Kalan was born in Tabriz, Iran, in 1980. He received the
B.Sc. degree
in Radiology from the Tabriz University of Medical sciences, Tabriz, Iran in 2004, and
the MSc. and Ph.D. degrees in Anatomical sciences from the Tabriz University of
Medical Sciences, Tabriz, Iran, in 2006 and 2014, respectively. In 2014, he joined the
Department of Cognitive and neurosciences, faculty of advanced medical sciences,
Tabriz University of Medical Sciences, Tabriz, Iran; as an assistant professor. His current
research interests include neurosciences, regenerative medicine, nano medicine and
animal model of Multiple Sclerosis, Spinal cord injury and Alzheimer Disease. He is a
Life Member of the Iranian anatomical sciences association and Neurosciences Society.
e:
ebrahimiab@tbzmed.ac.irApplication of nano-sciences in modification of mechanistic/mammalian target of rapamycin signaling
pathway in cancers
Abbas Ebrahimi-kalan
1
,Forough Alemi serej
1
, Mohammad Ebrahimi kalan
2
, Ahmad mehdipour
1
, Zeynab Aliyari Serej
1
and
Mohammad Pourhassan-Moghaddam
1
1
Tabriz University of Medical Sciences, Iran
2
Florida International University, USA